Fidelity Investments
PRLD icon

Fidelity Investments’s Prelude Therapeutics PRLD Stock Holding History

Fidelity Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Sell
5,629
-380
-6% -$1.65K ﹤0.01% 4519
2026
Q1 		$20.6K Sell
6,009
-143
-2% -$375 ﹤0.01% 4503
2025
Q4 		$17.8K Sell
6,152
-2,947
-32% -$4.97K ﹤0.01% 4514
2025
Q3 		$13.1K Sell
9,099
-2,068
-19% -$2.07K ﹤0.01% 4525
2025
Q2 		$9.04K Sell
11,167
-9,071
-45% -$7.86K ﹤0.01% 4558
2025
Q1 		$15.5K Buy
20,238
+11,736
+138% +$10.9K ﹤0.01% 4325
2024
Q4 		$10.8K Buy
8,502
+884
+12% +$1.17K ﹤0.01% 4443
2024
Q3 		$15.8K Sell
7,618
-1,957
-20% -$9.06K ﹤0.01% 4283
2024
Q2 		$36.5K Sell
9,575
-1,975
-17% -$8.04K ﹤0.01% 3784
2024
Q1 		$54.7K Sell
11,550
-253,137
-96% -$985K ﹤0.01% 3541
2023
Q4 		$1.13M Sell
264,687
-4,866,746
-95% -$14.8M ﹤0.01% 2439
2023
Q3 		$15.9M Sell
5,131,433
-808,787
-14% -$3.03M ﹤0.01% 1672
2023
Q2 		$26.7M Buy
5,940,220
+1,393,542
+31% +$8.33M ﹤0.01% 1523
2023
Q1 		$25.9M Sell
4,546,678
-42,914
-0.9% -$262K ﹤0.01% 1512
2022
Q4 		$27.7M Sell
4,589,592
-48,955
-1% -$314K ﹤0.01% 1489
2022
Q3 		$30.7M Buy
4,638,547
+335,578
+8% +$2.26M ﹤0.01% 1446
2022
Q2 		$22.5M Sell
4,302,969
-1,068,938
-20% -$5.44M ﹤0.01% 1605
2022
Q1 		$37.1M Sell
5,371,907
-567,026
-10% -$5.19M ﹤0.01% 1518
2021
Q4 		$73.9M Sell
5,938,933
-1,116,733
-16% -$18.2M 0.01% 1253
2021
Q3 		$220M Buy
7,055,666
+503,167
+8% +$16.3M 0.02% 763
2021
Q2 		$188M Buy
6,552,499
+300,392
+5% +$10.7M 0.01% 855
2021
Q1 		$271M Buy
6,252,107
+2,042,144
+49% +$135M 0.02% 650
2020
Q4 		$296M Buy
4,209,963
+1,081,579
+35% +$53.8M 0.03% 584
2020
Q3 		$90.1M Buy
+3,128,384
New +$88.3M 0.01% 955

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Fidelity Investments's PRLD Position: Q2 2026 in Review

Fidelity Investments reduced its Prelude Therapeutics (PRLD) stake by 6.3% in Q2 2026, selling an estimated $1.65K and leaving 5,629 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #4519.

Fidelity Investments first reported a position in PRLD in Q3 2020 and has held it in 24 quarters since. The position peaked at $296M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Fidelity Investments held 5,629 shares of Prelude Therapeutics worth $30K as of Q2 2026.
  • Fidelity Investments sold 380 Prelude Therapeutics shares in Q2 2026, an estimated $1.65K.
  • Prelude Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4519 holding.
  • Fidelity Investments first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Prelude Therapeutics position peaked at $296M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.